● Home  

● Random  

● Nearby  



● Log in  



● Settings  



● Donate  



● About Wikipedia  

● Disclaimers  



Wikipedia





Antiestrogen





● Article  
● Talk  


● Language  

● Watch  

● Edit  





Antiestrogens, also known as estrogen antagonistsorestrogen blockers, are a class of drugs which prevent estrogens like estradiol from mediating their biological effects in the body. They act by blocking the estrogen receptor (ER) and/or inhibitingorsuppressing estrogen production.[1][2] Antiestrogens are one of three types of sex hormone antagonists, the others being antiandrogens and antiprogestogens.[3] Antiestrogens are commonly used to stop steroid hormones, estrogen, from binding to the estrogen receptors leading to the decrease of estrogen levels.[4] Decreased levels of estrogen can lead to complications in sexual development.[5] Antiandrogens are sex hormone antagonists which are able to lower the production and the effects that testosterone can have on female bodies.[6]

Antiestrogen
Drug class
Fulvestrant, a steroidal antiestrogen and a drug used in the treatment of breast cancer.
Class identifiers
SynonymsEstrogen antagonists; Estrogen blockers; Estradiol antagonists
UseBreast cancer; Infertility; Male hypogonadism; Gynecomastia; transgender men
ATC codeL02BA
Biological targetEstrogen receptor
Chemical classSteroidal; Nonsteroidal (triphenylethylene, others)
External links
MeSHD020847
Legal status
In Wikidata

Types and examples

edit

Antiestrogens include selective estrogen receptor modulators (SERMs) like tamoxifen, clomifene, and raloxifene, the ER silent antagonist and selective estrogen receptor degrader (SERD) fulvestrant,[7][8] aromatase inhibitors (AIs) like anastrozole, and antigonadotropins including androgens/anabolic steroids, progestogens, and GnRH analogues.

Estrogen receptors (ER) like ERα and ERβ include activation function 1 (AF1) domain and activation function 2 (AF2) domain in which SERMS act as antagonists for the AF2 domain, while “pure” antiestrogens like ICI 182,780 and ICI 164,384 are antagonists for the AF1 and AF2 domains.[9]

Although aromatase inhibitors and antigonadotropins can be considered antiestrogens by some definitions, they are often treated as distinct classes.[10] Aromatase inhibitors and antigonadotropins reduce the production of estrogen, while the term "antiestrogen" is often reserved for agents reducing the response to estrogen.[11]

Medical uses

edit

Antiestrogens are used for:

Side effects

edit

Inwomen, the side effects of antiestrogens include hot flashes, osteoporosis, breast atrophy, vaginal dryness, and vaginal atrophy. In addition, they may cause depression and reduced libido.

Pharmacology

edit

Antiestrogens act as antagonists of the estrogen receptors, ERα and ERβ.

  • t
  • e
    • Affinities of estrogen receptor ligands for the ERα and ERβ
    Ligand Other names Relative binding affinities (RBA, %)a Absolute binding affinities (Ki, nM)a Action
    ERα ERβ ERα ERβ
    Estradiol E2; 17β-Estradiol 100 100 0.115 (0.04–0.24) 0.15 (0.10–2.08) Estrogen
    Estrone E1; 17-Ketoestradiol 16.39 (0.7–60) 6.5 (1.36–52) 0.445 (0.3–1.01) 1.75 (0.35–9.24) Estrogen
    Estriol E3; 16α-OH-17β-E2 12.65 (4.03–56) 26 (14.0–44.6) 0.45 (0.35–1.4) 0.7 (0.63–0.7) Estrogen
    Estetrol E4; 15α,16α-Di-OH-17β-E2 4.0 3.0 4.9 19 Estrogen
    Alfatradiol 17α-Estradiol 20.5 (7–80.1) 8.195 (2–42) 0.2–0.52 0.43–1.2 Metabolite
    16-Epiestriol 16β-Hydroxy-17β-estradiol 7.795 (4.94–63) 50 ? ? Metabolite
    17-Epiestriol 16α-Hydroxy-17α-estradiol 55.45 (29–103) 79–80 ? ? Metabolite
    16,17-Epiestriol 16β-Hydroxy-17α-estradiol 1.0 13 ? ? Metabolite
    2-Hydroxyestradiol 2-OH-E2 22 (7–81) 11–35 2.5 1.3 Metabolite
    2-Methoxyestradiol 2-MeO-E2 0.0027–2.0 1.0 ? ? Metabolite
    4-Hydroxyestradiol 4-OH-E2 13 (8–70) 7–56 1.0 1.9 Metabolite
    4-Methoxyestradiol 4-MeO-E2 2.0 1.0 ? ? Metabolite
    2-Hydroxyestrone 2-OH-E1 2.0–4.0 0.2–0.4 ? ? Metabolite
    2-Methoxyestrone 2-MeO-E1 <0.001–<1 <1 ? ? Metabolite
    4-Hydroxyestrone 4-OH-E1 1.0–2.0 1.0 ? ? Metabolite
    4-Methoxyestrone 4-MeO-E1 <1 <1 ? ? Metabolite
    16α-Hydroxyestrone 16α-OH-E1; 17-Ketoestriol 2.0–6.5 35 ? ? Metabolite
    2-Hydroxyestriol 2-OH-E3 2.0 1.0 ? ? Metabolite
    4-Methoxyestriol 4-MeO-E3 1.0 1.0 ? ? Metabolite
    Estradiol sulfate E2S; Estradiol 3-sulfate <1 <1 ? ? Metabolite
    Estradiol disulfate Estradiol 3,17β-disulfate 0.0004 ? ? ? Metabolite
    Estradiol 3-glucuronide E2-3G 0.0079 ? ? ? Metabolite
    Estradiol 17β-glucuronide E2-17G 0.0015 ? ? ? Metabolite
    Estradiol 3-gluc. 17β-sulfate E2-3G-17S 0.0001 ? ? ? Metabolite
    Estrone sulfate E1S; Estrone 3-sulfate <1 <1 >10 >10 Metabolite
    Estradiol benzoate EB; Estradiol 3-benzoate 10 ? ? ? Estrogen
    Estradiol 17β-benzoate E2-17B 11.3 32.6 ? ? Estrogen
    Estrone methyl ether Estrone 3-methyl ether 0.145 ? ? ? Estrogen
    ent-Estradiol 1-Estradiol 1.31–12.34 9.44–80.07 ? ? Estrogen
    Equilin 7-Dehydroestrone 13 (4.0–28.9) 13.0–49 0.79 0.36 Estrogen
    Equilenin 6,8-Didehydroestrone 2.0–15 7.0–20 0.64 0.62 Estrogen
    17β-Dihydroequilin 7-Dehydro-17β-estradiol 7.9–113 7.9–108 0.09 0.17 Estrogen
    17α-Dihydroequilin 7-Dehydro-17α-estradiol 18.6 (18–41) 14–32 0.24 0.57 Estrogen
    17β-Dihydroequilenin 6,8-Didehydro-17β-estradiol 35–68 90–100 0.15 0.20 Estrogen
    17α-Dihydroequilenin 6,8-Didehydro-17α-estradiol 20 49 0.50 0.37 Estrogen
    Δ8-Estradiol 8,9-Dehydro-17β-estradiol 68 72 0.15 0.25 Estrogen
    Δ8-Estrone 8,9-Dehydroestrone 19 32 0.52 0.57 Estrogen
    Ethinylestradiol EE; 17α-Ethynyl-17β-E2 120.9 (68.8–480) 44.4 (2.0–144) 0.02–0.05 0.29–0.81 Estrogen
    Mestranol EE 3-methyl ether ? 2.5 ? ? Estrogen
    Moxestrol RU-2858; 11β-Methoxy-EE 35–43 5–20 0.5 2.6 Estrogen
    Methylestradiol 17α-Methyl-17β-estradiol 70 44 ? ? Estrogen
    Diethylstilbestrol DES; Stilbestrol 129.5 (89.1–468) 219.63 (61.2–295) 0.04 0.05 Estrogen
    Hexestrol Dihydrodiethylstilbestrol 153.6 (31–302) 60–234 0.06 0.06 Estrogen
    Dienestrol Dehydrostilbestrol 37 (20.4–223) 56–404 0.05 0.03 Estrogen
    Benzestrol (B2) – 114 ? ? ? Estrogen
    Chlorotrianisene TACE 1.74 ? 15.30 ? Estrogen
    Triphenylethylene TPE 0.074 ? ? ? Estrogen
    Triphenylbromoethylene TPBE 2.69 ? ? ? Estrogen
    Tamoxifen ICI-46,474 3 (0.1–47) 3.33 (0.28–6) 3.4–9.69 2.5 SERM
    Afimoxifene 4-Hydroxytamoxifen; 4-OHT 100.1 (1.7–257) 10 (0.98–339) 2.3 (0.1–3.61) 0.04–4.8 SERM
    Toremifene 4-Chlorotamoxifen; 4-CT ? ? 7.14–20.3 15.4 SERM
    Clomifene MRL-41 25 (19.2–37.2) 12 0.9 1.2 SERM
    Cyclofenil F-6066; Sexovid 151–152 243 ? ? SERM
    Nafoxidine U-11,000A 30.9–44 16 0.3 0.8 SERM
    Raloxifene – 41.2 (7.8–69) 5.34 (0.54–16) 0.188–0.52 20.2 SERM
    Arzoxifene LY-353,381 ? ? 0.179 ? SERM
    Lasofoxifene CP-336,156 10.2–166 19.0 0.229 ? SERM
    Ormeloxifene Centchroman ? ? 0.313 ? SERM
    Levormeloxifene 6720-CDRI; NNC-460,020 1.55 1.88 ? ? SERM
    Ospemifene Deaminohydroxytoremifene 0.82–2.63 0.59–1.22 ? ? SERM
    Bazedoxifene – ? ? 0.053 ? SERM
    Etacstil GW-5638 4.30 11.5 ? ? SERM
    ICI-164,384 – 63.5 (3.70–97.7) 166 0.2 0.08 Antiestrogen
    Fulvestrant ICI-182,780 43.5 (9.4–325) 21.65 (2.05–40.5) 0.42 1.3 Antiestrogen
    Propylpyrazoletriol PPT 49 (10.0–89.1) 0.12 0.40 92.8 ERα agonist
    16α-LE2 16α-Lactone-17β-estradiol 14.6–57 0.089 0.27 131 ERα agonist
    16α-Iodo-E2 16α-Iodo-17β-estradiol 30.2 2.30 ? ? ERα agonist
    Methylpiperidinopyrazole MPP 11 0.05 ? ? ERα antagonist
    Diarylpropionitrile DPN 0.12–0.25 6.6–18 32.4 1.7 ERβ agonist
    8β-VE2 8β-Vinyl-17β-estradiol 0.35 22.0–83 12.9 0.50 ERβ agonist
    Prinaberel ERB-041; WAY-202,041 0.27 67–72 ? ? ERβ agonist
    ERB-196 WAY-202,196 ? 180 ? ? ERβ agonist
    Erteberel SERBA-1; LY-500,307 ? ? 2.68 0.19 ERβ agonist
    SERBA-2 – ? ? 14.5 1.54 ERβ agonist
    Coumestrol – 9.225 (0.0117–94) 64.125 (0.41–185) 0.14–80.0 0.07–27.0 Xenoestrogen
    Genistein – 0.445 (0.0012–16) 33.42 (0.86–87) 2.6–126 0.3–12.8 Xenoestrogen
    Equol – 0.2–0.287 0.85 (0.10–2.85) ? ? Xenoestrogen
    Daidzein – 0.07 (0.0018–9.3) 0.7865 (0.04–17.1) 2.0 85.3 Xenoestrogen
    Biochanin A – 0.04 (0.022–0.15) 0.6225 (0.010–1.2) 174 8.9 Xenoestrogen
    Kaempferol – 0.07 (0.029–0.10) 2.2 (0.002–3.00) ? ? Xenoestrogen
    Naringenin – 0.0054 (<0.001–0.01) 0.15 (0.11–0.33) ? ? Xenoestrogen
    8-Prenylnaringenin 8-PN 4.4 ? ? ? Xenoestrogen
    Quercetin – <0.001–0.01 0.002–0.040 ? ? Xenoestrogen
    Ipriflavone – <0.01 <0.01 ? ? Xenoestrogen
    Miroestrol – 0.39 ? ? ? Xenoestrogen
    Deoxymiroestrol – 2.0 ? ? ? Xenoestrogen
    β-Sitosterol – <0.001–0.0875 <0.001–0.016 ? ? Xenoestrogen
    Resveratrol – <0.001–0.0032 ? ? ? Xenoestrogen
    α-Zearalenol – 48 (13–52.5) ? ? ? Xenoestrogen
    β-Zearalenol – 0.6 (0.032–13) ? ? ? Xenoestrogen
    Zeranol α-Zearalanol 48–111 ? ? ? Xenoestrogen
    Taleranol β-Zearalanol 16 (13–17.8) 14 0.8 0.9 Xenoestrogen
    Zearalenone ZEN 7.68 (2.04–28) 9.45 (2.43–31.5) ? ? Xenoestrogen
    Zearalanone ZAN 0.51 ? ? ? Xenoestrogen
    Bisphenol A BPA 0.0315 (0.008–1.0) 0.135 (0.002–4.23) 195 35 Xenoestrogen
    Endosulfan EDS <0.001–<0.01 <0.01 ? ? Xenoestrogen
    Kepone Chlordecone 0.0069–0.2 ? ? ? Xenoestrogen
    o,p'-DDT – 0.0073–0.4 ? ? ? Xenoestrogen
    p,p'-DDT – 0.03 ? ? ? Xenoestrogen
    Methoxychlor p,p'-Dimethoxy-DDT 0.01 (<0.001–0.02) 0.01–0.13 ? ? Xenoestrogen
    HPTE Hydroxychlor; p,p'-OH-DDT 1.2–1.7 ? ? ? Xenoestrogen
    Testosterone T; 4-Androstenolone <0.0001–<0.01 <0.002–0.040 >5000 >5000 Androgen
    Dihydrotestosterone DHT; 5α-Androstanolone 0.01 (<0.001–0.05) 0.0059–0.17 221–>5000 73–1688 Androgen
    Nandrolone 19-Nortestosterone; 19-NT 0.01 0.23 765 53 Androgen
    Dehydroepiandrosterone DHEA; Prasterone 0.038 (<0.001–0.04) 0.019–0.07 245–1053 163–515 Androgen
    5-Androstenediol A5; Androstenediol 6 17 3.6 0.9 Androgen
    4-Androstenediol – 0.5 0.6 23 19 Androgen
    4-Androstenedione A4; Androstenedione <0.01 <0.01 >10000 >10000 Androgen
    3α-Androstanediol 3α-Adiol 0.07 0.3 260 48 Androgen
    3β-Androstanediol 3β-Adiol 3 7 6 2 Androgen
    Androstanedione 5α-Androstanedione <0.01 <0.01 >10000 >10000 Androgen
    Etiocholanedione 5β-Androstanedione <0.01 <0.01 >10000 >10000 Androgen
    Methyltestosterone 17α-Methyltestosterone <0.0001 ? ? ? Androgen
    Ethinyl-3α-androstanediol 17α-Ethynyl-3α-adiol 4.0 <0.07 ? ? Estrogen
    Ethinyl-3β-androstanediol 17α-Ethynyl-3β-adiol 50 5.6 ? ? Estrogen
    Progesterone P4; 4-Pregnenedione <0.001–0.6 <0.001–0.010 ? ? Progestogen
    Norethisterone NET; 17α-Ethynyl-19-NT 0.085 (0.0015–<0.1) 0.1 (0.01–0.3) 152 1084 Progestogen
    Norethynodrel 5(10)-Norethisterone 0.5 (0.3–0.7) <0.1–0.22 14 53 Progestogen
    Tibolone 7α-Methylnorethynodrel 0.5 (0.45–2.0) 0.2–0.076 ? ? Progestogen
    Δ4-Tibolone 7α-Methylnorethisterone 0.069–<0.1 0.027–<0.1 ? ? Progestogen
    3α-Hydroxytibolone – 2.5 (1.06–5.0) 0.6–0.8 ? ? Progestogen
    3β-Hydroxytibolone – 1.6 (0.75–1.9) 0.070–0.1 ? ? Progestogen
    Footnotes: a = (1) Binding affinity values are of the format "median (range)" (# (#–#)), "range" (#–#), or "value" (#) depending on the values available. The full sets of values within the ranges can be found in the Wiki code. (2) Binding affinities were determined via displacement studies in a variety of in-vitro systems with labeled estradiol and human ERα and ERβ proteins (except the ERβ values from Kuiper et al. (1997), which are rat ERβ). Sources: See template page.

    History

    edit

    The first nonsteroidal antiestrogen was discovered by Lerner and coworkers in 1958.[12] Ethamoxytriphetol (MER-25) was the first antagonist of the ER to be discovered,[13] followed by clomifene and tamoxifen.[14][15]

    See also

    edit

    References

    edit
    1. ^ "Definition of antiestrogen - NCI Dictionary of Cancer Terms, Definition of antiestrogen - NCI Dictionary of Cancer Terms".,
  • ^ "antiestrogen"atDorland's Medical Dictionary
  • ^ Nath JL (2006). Using Medical Terminology: A Practical Approach. Lippincott Williams & Wilkins. pp. 977–. ISBN 978-0-7817-4868-1.
  • ^ McKeage K, Curran MP, Plosker GL (2004-03-01). "Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy". Drugs. 64 (6): 633–48. doi:10.2165/00003495-200464060-00009. PMID 15018596. S2CID 242916244.
  • ^ Amenyogbe E, Chen G, Wang Z, Lu X, Lin M, Lin AY (2020-02-07). "A Review on Sex Steroid Hormone Estrogen Receptors in Mammals and Fish". International Journal of Endocrinology. 2020: 5386193. doi:10.1155/2020/5386193. PMC 7029290. PMID 32089683.
  • ^ Angus LM, Nolan BJ, Zajac JD, Cheung AS (September 2020). "A systematic review of antiandrogens and feminization in transgender women". Clinical Endocrinology. 94 (5): 743–752. doi:10.1111/cen.14329. hdl:11343/276405. PMID 32926454.
  • ^ Ottow E, Weinmann H (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 164–165. ISBN 978-3-527-62330-3.
  • ^ Chabner BA, Longo DL (8 November 2010). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. pp. 660–. ISBN 978-1-60547-431-1.
  • ^ Pike, Ashley C.W.; Brzozowski, A.Marek; Walton, Julia; Hubbard, Roderick E.; Thorsell, Ann-Gerd; Li, Yi-Lin; Gustafsson, Jan-Åke; Carlquist, Mats (2001-02-01). "Structural Insights into the Mode of Action of a Pure Antiestrogen". Structure. 9 (2): 145–153. doi:10.1016/S0969-2126(01)00568-8. ISSN 0969-2126. PMID 11250199.
  • ^ Riggins RB, Bouton AH, Liu MC, Clarke R (2005). Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitamins & Hormones. Vol. 71. pp. 201–37. doi:10.1016/S0083-6729(05)71007-4. ISBN 9780127098715. PMID 16112269.
  • ^ Thiantanawat A, Long BJ, Brodie AM (November 2003). "Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens". Cancer Research. 63 (22): 8037–50. PMID 14633737.
  • ^ MacGregor JI, Jordan VC (June 1998). "Basic guide to the mechanisms of antiestrogen action". Pharmacological Reviews. 50 (2): 151–96. PMID 9647865.
  • ^ Maximov PY, McDaniel RE, Jordan VC (23 July 2013). Tamoxifen: Pioneering Medicine in Breast Cancer. Springer Science & Business Media. pp. 7–. ISBN 978-3-0348-0664-0.
  • ^ Jordan VC (27 May 2013). Estrogen Action, Selective Estrogen Receptor Modulators and Women's Health: Progress and Promise. World Scientific. pp. 7, 112. ISBN 978-1-84816-959-3.
  • ^ Sneader W (23 June 2005). Drug Discovery: A History. John Wiley & Sons. pp. 198–199. ISBN 978-0-471-89979-2.
    • edit

      This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.


    Retrieved from "https://en.wikipedia.org/w/index.php?title=Antiestrogen&oldid=1193552437"
      



    Last edited on 4 January 2024, at 11:32  





    Languages

     


    ●Deutsch
     ●Español
     ●فارسی
     ●Bahasa Indonesia
     ●Polski
     ●کوردی
     ●Tiếng Việt
      

     Wikipedia


    ●This page was last edited on 4 January 2024, at 11:32 (UTC).
    ●Content is available under CC BY-SA 4.0 unless otherwise noted.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Terms of Use
    ●Desktop